30mg Tirzepatide Peptide Dosage: Why This Figure Doesn't Exist in UK Practice

Step 1: Understanding the UK dose ceiling and why 30mg is outside it

Tirzepatide in the UK is available as Mounjaro in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, each delivered via a pre-filled KwikPen. The 15mg pen is the highest strength the MHRA has licensed, and the clinical trials that led to that approval (including SURMOUNT-1, published in the New England Journal of Medicine) tested doses up to that ceiling. Researchers found average weight reduction of around 20–21% at 15mg over 72 weeks. There was no 30mg arm because no higher dose was submitted for approval.

The figure of 30mg appears occasionally in two contexts: compounded tirzepatide peptides, such as the 5mg research-grade preparations sold to research laboratories (not for human therapeutic use in the UK), and certain US compounding pharmacy preparations that existed during a period of shortage. None of these are obtainable through a licensed UK pharmacy, and none have gone through the quality and safety assessment that the Mounjaro product has. The gap between a raw peptide compound and a licensed medicine is not a bureaucratic formality, it covers manufacturing standards, sterility, accurate dose delivery and batch testing.

If you have found a supplier offering 30mg tirzepatide for weight loss and claiming it is equivalent to Mounjaro, that is a significant red flag. The MHRA has warned about unlicensed and counterfeit weight-loss products, and you can report suspect sellers at the MHRA's Yellow Card scheme. Worth checking before you part with money or inject anything.

Step 2: How the licensed titration schedule actually works

The reason tirzepatide is started at 2.5mg (and only moved upward over months) is to give the body time to adjust. Nausea and other gastrointestinal effects tend to be most noticeable at the beginning of treatment or after a dose increase; a slow climb through the strengths reduces the chance of those effects becoming severe enough to stop treatment. The 2.5mg starting pen's job is adjustment, full stop. It is not expected to produce substantial weight loss at that level.

From 2.5mg, a prescriber will typically consider moving to 5mg after four weeks, then 7.5mg, and so on. No step is mandatory, if a particular dose is well tolerated and effective, the prescriber and patient may agree to stay there rather than going higher. The 15mg dose is the maximum the prescriber can offer; there is simply no licensed rung above it. You can read more about what each stage looks like in practice on our tirzepatide dosage overview.

Each dose increase in private practice requires a clinical review. At nume, a GPhC-registered Independent Prescriber reads through your records before any change, a person, not automated software. That review checks that the previous dose was tolerated, considers any new symptoms, and confirms the increase is appropriate for you specifically.

Step 3: What to do if you've already sourced an unlicensed product

If you are currently using a compounded or research-grade tirzepatide product, the practical first step is to stop and speak to a healthcare professional. This is not a judgment, many people sought these routes because licensed treatment felt inaccessible, either through NHS waiting lists or cost. The concern is straightforwardly clinical: the concentration, sterility and actual peptide content of unlicensed products cannot be verified, and injecting the wrong dose carries real risks including hypoglycaemia in susceptible individuals and severe injection-site reactions.

Switching to the licensed Mounjaro route means starting again at 2.5mg under prescriber supervision, even if you've been on a higher dose elsewhere, a prescriber needs to establish your baseline safely. Our Mounjaro treatment page explains how the licensed product works and what a private consultation involves. For broader context on the cost of licensed treatment and what factors drive it, our page on Eli Lilly's UK price changes gives an honest picture of the private market.

The NHS tirzepatide patient information page is also a reliable starting point for understanding side effects, what to watch for, and when to seek urgent help. A plain, clinical read, no sales language, just the facts a pharmacist would want you to have.

When the 15mg dose isn't producing results

A question our prescribers hear regularly: what if someone reaches 15mg and weight loss has stalled? The licensed answer is that NICE guidance (TA1026) suggests reviewing continuation if less than 5% weight loss has occurred after six months at the highest tolerated dose. The right conversation at that point is with your prescriber, not an internet search for higher doses.

There are legitimate adjustments a prescriber can explore: reviewing diet and activity patterns alongside the medicine, considering whether a different GLP-1 option might suit you better, or assessing whether there are other clinical factors at play. What is not a legitimate path is sourcing a higher-concentration unlicensed peptide. The dose in a licensed medicine is calibrated precisely; doubling it outside clinical oversight is not a shortcut to better results.

If you are exploring what licensed tirzepatide treatment at 10mg or 15mg involves, our pages on tirzepatide 10mg and the 30mg dosage question in more detail cover the ground thoroughly. And if you are ready to begin a conversation with a prescriber about whether licensed treatment is right for you, a free consultation is the place to start.